|
|
|
|
|
||||||||||||
|
|
|
|
|
|
|
|
價值評估 |
盈利(現時/預測)
-8.52/-1.03
|
企業價值
8.64M
|
資產負債 |
每股賬面淨值
1.62
|
現金流量 |
現金流量率
--
|
損益表 |
收益
0
|
每股收益
--
|
同行比較
|
||||||||||||||||||||||||||||||||||||||||||||||||
|
報價延遲最少15分鐘:2024/05/17 15:32 EDT
同行比較之報價最少15分鐘延遲
業務概覽
|
|||
Portage Biotech Inc is engaged in researching and developing pharmaceutical and biotech products through to clinical proof of concept with an initial focus on unmet clinical needs. It is an immune-oncology company focused on overcoming immune resistance and currently managing 10 immuno-oncology assets at various development stages. Its pipeline products include IMM-60; IMM60 + Cell Therapy; (IMM60 / NY-ESO-1) + Keytruda and others. |